Reference(s)
Click here to return to the Reference Table

Cancer type: Head and Neck


HGF/SF expression

Reference Number: 50
Marshall, D. D. & Kornberg, L. J. Overexpression of scatter factor and its receptor (c-met) in oral squamous cell carcinoma. Laryngoscope 108, 1413-7 (1998).
PubMed link      E-mail link

Reference Number: 51
Uchida, D. et al. Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int J Cancer 93, 489-96 (2001).
PubMed link      E-mail link

Reference Number: 259
Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K, Joensuu H. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res 9:68-75 (2003).
PubMed link      E-mail link

Reference Number: 399
Aoki T, Tsukinoki K, Kurabayashi H, Sasaki M, Yasuda M, Ota Y, Watanabe Y, Kaneko A. Hepatocyte growth factor expression correlates with cyclooxygenase-2 pathway in human salivary gland tumors. Oral Oncol. 42, 51-6 (2006)
PubMed link      E-mail link

Reference Number: 406
Druzgal CH, Chen Z, Yeh NT, Thomas GR, Ondrey FG, Duffey DC, Vilela RJ, Ende K, McCullagh L, Rudy SF, Muir C, Herscher LL, Morris JC, Albert PS, Van Waes C. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma. Head Neck27, 771-84 (2005)
PubMed link      E-mail link

Reference Number: 484
Kim CH, Moon SK, Bae JH, Lee JH, Han JH, Kim K, Choi EC. Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma. Acta Otolaryngol. 126, 88-94 (2006)
PubMed link      E-mail link

Reference Number: 629
Kim CH, Lee JS, Kang SO, Bae JH, Hong SP, Kahng H. Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma. Oral Oncol. 43, 1021-5 (2007)
PubMed link      E-mail link

Reference Number: 639
Kim CH, Kim J, Kahng H, Choi EC. Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma. Ann Surg Oncol. 14, 1565-74 (2007)
PubMed link      E-mail link

Reference Number: 655
Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, Morgan S, Ferris RL, Grandis JR, Siegfried JM. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res. 15, 3740-50 (2009)
PubMed link      E-mail link

Reference Number: 668
Hara S, Nakashiro K, Goda H, Hamakawa H. Role of Akt isoforms in HGF-induced invasive growth of human salivary gland cancer cells. Biochem Biophys Res Commun. 370, 123-8 (2008)
PubMed link      E-mail link

Reference Number: 801
Xie LQ, Bian LJ, Li Z, Li Y, Li ZX, Li B. Altered expression of E-cadherin by hepatocyte growth factor and effect on the prognosis of nasopharyngeal carcinoma. Ann Surg Oncol. 17, 1927-36 (2010)
PubMed link      E-mail link

Reference Number: 926
Scianna M, Merks RM, Preziosi L, Medico E. Individual cell-based models of cell scatter of ARO and MLP-29 cells in response to hepatocyte growth factor. J Theor Biol. 260, 151-60 (2009)
PubMed link      E-mail link

Reference Number: 968
Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 69, 3021-31 (2009)
PubMed link      E-mail link

Reference Number: 1037
Susuki D, Kimura S, Naganuma S, Tsuchiyama K, Tanaka T, Kitamura N, Fujieda S, Itoh H. Regulation of microRNA expression by hepatocyte growth factor in human head and neck squamous cell carcinoma. Cancer Sci. 102, 2164-71 (2011)
PubMed link      E-mail link

Reference Number: 1144
Le QT, Fisher R, Oliner KS, Young RJ, Cao H, Kong C, Graves E, Hicks RJ, McArthur GA, Peters L, O'Sullivan B, Giaccia A, Rischin D. Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer. Clin Cancer Res. 18, 1798-807 (2012)
PubMed link      E-mail link

Reference Number: 1287
Singleton KR, Kim J, Hinz TK, Marek LA, Casás-Selves M, Hatheway C, Tan AC, DeGregori J, Heasley LE. A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines. Mol Pharmacol. 83, 882-93 (2013)
PubMed link      E-mail link

Reference Number: 1611
Koo BS, Kim JM, Seo ST, Yoon YH, Kwon KR, Kim SH, Kwon HW, Bae WJ, Lim YC. Upregulation of HGF and c-MET is associated with subclinical central lymph node metastasis in papillary thyroid microcarcinoma. Ann Surg Oncol. 21, 2310-7 (2014)
PubMed link      E-mail link

Met expression

Reference Number: 50
Marshall, D. D. & Kornberg, L. J. Overexpression of scatter factor and its receptor (c-met) in oral squamous cell carcinoma. Laryngoscope 108, 1413-7 (1998).
PubMed link      E-mail link

Reference Number: 52
Aebersold, D. M. et al. Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. Int J Cancer 96, 41-54 (2001).
PubMed link      E-mail link

Reference Number: 53
Cortesina, G. et al. Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases. Int J Cancer 89, 286-92. (2000).
PubMed link      E-mail link

Reference Number: 54
Galeazzi, E. et al. Detection of MET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas. Eur Arch Otorhinolaryngol 254 Suppl 1, S138-43 (1997).
PubMed link      E-mail link

Reference Number: 55
Morello, S. et al. MET receptor is overexpressed but not mutated in oral squamous cell carcinomas. J Cell Physiol 189, 285-90 (2001).
PubMed link      E-mail link

Reference Number: 56
Sawatsubashi, M., Sasatomi, E., Mizokami, H., Tokunaga, O. & Shin, T. Expression of c-Met in laryngeal carcinoma. Virchows Arch 432, 331-5 (1998).
PubMed link      E-mail link

Reference Number: 260
Suzuki K, Cheng J, Watanabe Y. Hepatocyte growth factor and c-Met (HGF/c-Met) in adenoid cystic carcinoma of the human salivary gland. J Oral Pathol Med 32:84-9 (2003).
PubMed link      E-mail link

Reference Number: 484
Kim CH, Moon SK, Bae JH, Lee JH, Han JH, Kim K, Choi EC. Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma. Acta Otolaryngol. 126, 88-94 (2006)
PubMed link      E-mail link

Reference Number: 489
Lo Muzio L, Farina A, Coccia E, Capogreco M, Colella G, Leonardi R, Campisi G, Carinci F. Effect of c-Met expression on survival in head and neck squamous cell carcinoma. Tumour Biol. 27, 115-21 (2006)
PubMed link      E-mail link

Reference Number: 512
Hara S, Nakashiro K, Klosek SK, Ishikawa T, Shintani S, Hamakawa H. Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. Oral Oncol. 42, 593-8 (2006)
PubMed link      E-mail link

Reference Number: 537
Endo K, Shirai A, Furukawa M, Yoshizaki T. Prognostic value of cell motility activation factors in patients with tongue squamous cell carcinoma. Hum Pathol. 37, 1111-6 (2006)
PubMed link      E-mail link

Reference Number: 655
Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, Morgan S, Ferris RL, Grandis JR, Siegfried JM. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res. 15, 3740-50 (2009)
PubMed link      E-mail link

Reference Number: 667
Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, Giaccone G, Albano R, Comoglio PM, van Dongen GA. Quantitative PET imaging of Met-expressing human cancer xenografts with (89)Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging. 2008 May 20. [Epub ahead of print]
PubMed link      E-mail link

Reference Number: 834
Cai KM, Bao XL, Kong XH, Jinag W, Mao MR, Chu JS, Huang YJ, Zhao XJ. Hsa-miR-34c suppresses growth and invasion of human laryngeal carcinoma cells via targeting c-Met. Int J Mol Med. 25, 565-71 (2010)
PubMed link      E-mail link

Reference Number: 907
Brusevold IJ, Søland TM, Khuu C, Christoffersen T, Bryne M. Nuclear and cytoplasmic expression of Met in oral squamous cell carcinoma and in an organotypic oral cancer model. Eur J Oral Sci. 118, 342-9 (2010)
PubMed link      E-mail link

Reference Number: 935
Kim CH, Koh YW, Han JH, Kim JW, Lee JS, Baek SJ, Hwang HS, Choi EC. c-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma. Head Neck. 32, 1655-64 (2010)
PubMed link      E-mail link

Reference Number: 968
Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 69, 3021-31 (2009)
PubMed link      E-mail link

Reference Number: 988
Sen B, Peng S, Saigal B, Williams MD, Johnson FM. Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Clin Cancer Res. 17, 514-24 (2011)
PubMed link      E-mail link

Reference Number: 1012
Qian CN, Guo X, Cao B, Kort EJ, Lee CC, Chen J, Wang LM, Mai WY, Min HQ, Hong MH, Vande Woude GF, Resau JH, Teh BT. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res. 62, 589-96 (2002)
PubMed link      E-mail link

Reference Number: 1046
Sun S, Wang Z. Head neck squamous cell carcinoma c-Met? cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis. Int J Cancer. 129, 2337-48 (2011)
PubMed link      E-mail link

Reference Number: 1100
Zhao D, Wang SH, Feng Y, Hua CG, Zhao J, Tang XF. Intratumoral c-Met expression is associated with vascular endothelial growth factor C expression, lymphangiogenesis, and lymph node metastasis in oral squamous cell carcinoma: implications for use as a prognostic marker. Hum Pathol. 42, 1514-23 (2011)
PubMed link      E-mail link

Reference Number: 1303
Lim YC, Han JH, Kang HJ, Kim YS, Lee BH, Choi EC, Kim CH. Overexpression of c-Met promotes invasion and metastasis of small oral tongue carcinoma. Oral Oncol. 48, 1114-9 (2012)
PubMed link      E-mail link

Reference Number: 1339
Stabile LP, He G, Lui VW, Thomas S, Henry C, Gubish CT, Joyce S, Quesnelle KM, Siegfried JM, Grandis JR. c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met. Clin Cancer Res. 19, 380-92 (2013)
PubMed link      E-mail link

Reference Number: 1354
Perisanidis C1, Wrba F, Brandstetter A, Kornek G, Mitchell D, Seemann R, Selzer E, Ewers R, Filipits M. Impact of epidermal growth factor receptor, mesenchymal-epithelial transition factor, and insulin-like growth factor receptor 1 expression on survival of patients with oral and oropharyngeal cancer. Br J Oral Maxillofac Surg. 51, 234-40 (2013)
PubMed link      E-mail link

Reference Number: 1383
Kumai T1, Matsuda Y, Oikawa K, Aoki N, Kimura S, Harabuchi Y, Celis E, Kobayashi H. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy. Br J Cancer. 109, 2155-66 (2013)
PubMed link      E-mail link

Reference Number: 1419
Akervall J1, Nandalur S2, Zhang J3, Qian CN3, Goldstein N4, Gyllerup P5, Gardinger Y5, Alm J5, Lorenc K5, Nilsson K5, Resau J3, Wilson G2, Teh B3 A novel panel of biomarkers predicts radioresistance in patients with squamous cell carcinoma of the head and neck. Eur J Cancer. 50, 570-81 (2014)
PubMed link      E-mail link

Reference Number: 1518
Rajamoorthi A1, Shrivastava S, Steele R, Nerurkar P, Gonzalez JG, Crawford S, Varvares M, Ray RB. Bitter melon reduces head and neck squamous cell carcinoma growth by targeting c-Met signaling. PLoS One. 8, e78006 (2013)
PubMed link      E-mail link

Reference Number: 1530
Zhou Y, Zhao C, Gery S, Braunstein GD, Okamoto R, Alvarez R, Miles SA, Doan NB, Said JW, Gu J, Phillip Koeffler H. Off-target effects of c-MET inhibitors on thyroid cancer cells. Mol Cancer Ther. 13, 134-43 (2014)
PubMed link      E-mail link

Reference Number: 1531
Tao X, Hill KS, Gaziova I, Sastry SK, Qui S, Szaniszlo P, Fennewald S, Resto VA, Elferink LA. Silencing Met receptor tyrosine kinase signaling decreased oral tumor growth and increased survival of nude mice. Oral Oncol. 50, 104-12 (2014)
PubMed link      E-mail link

Reference Number: 1586
Ettl T, Gosau M, Brockhoff G, Schwarz-Furlan S, Agaimy A, Reichert TE, Rohrmeier C, Zenk J, Iro H. Predictors of cervical lymph node metastasis in salivary gland cancer. Head Neck. 36, 517-23 (2014)
PubMed link      E-mail link

Reference Number: 1611
Koo BS, Kim JM, Seo ST, Yoon YH, Kwon KR, Kim SH, Kwon HW, Bae WJ, Lim YC. Upregulation of HGF and c-MET is associated with subclinical central lymph node metastasis in papillary thyroid microcarcinoma. Ann Surg Oncol. 21, 2310-7 (2014)
PubMed link      E-mail link

Reference Number: 1700
Lee BS, Kang S, Kim KA, Song YJ, Cheong KH, Cha HY, Kim CH. Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression. Cell Death Dis. 5:e1159 (2014)
PubMed link      E-mail link

Reference Number: 1701
Grugan KD, Vega ME, Wong GS, Diehl JA, Bass AJ, Wong KK, Nakagawa H, Rustgi AK. A common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion. Cancer Biol Ther. 14, 853-9 (2013)
PubMed link      E-mail link

Reference Number: 1769
Nisa L, Aebersold DM, Giger R, Zimmer Y, Medová M. Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer. Pharmacol Ther. 143, 337-49 (2014)
PubMed link      E-mail link

Reference Number: 1804
Vasconcelos AC, Wagner VP, Meurer L, Vargas PA, de Souza LB, Fonseca FP, Squarize CH, Castilho RM, Martins MD. Immunoprofile of c-MET/PI3K signaling in human salivary gland tumors. Oral Surg Oral Med Oral Pathol Oral Radiol. 120, 238-47 (2015)
PubMed link      E-mail link

Reference Number: 1849
Ettl T, Viale-Bouroncle S, Hautmann MG, Gosau M, Kölbl O, Reichert TE, Morsczeck C. AKT and MET signalling mediates antiapoptotic radioresistance in head neck cancer cell lines. Oral Oncol. 51, 158-63 (2015)
PubMed link      E-mail link

Reference Number: 1877
Bell D, Ferrarotto R, Fox MD, Roberts D, Hanna EY, Weber RS, El-Naggar AK. Analysis and significance of c-MET expression in adenoid cystic carcinoma of the salivary gland. Cancer Biol Ther. 16, 834-8 (2015)
PubMed link      E-mail link

Reference Number: 1889
Ozawa Y, Nakamura Y, Fujishima F, Felizola SJ, Takeda K, Okamoto H, Ito K, Ishida H, Konno T, Kamei T, Miyata G, Ohuchi N, Sasano H. c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target. BMC Cancer. 15, 451 (2015)
PubMed link      E-mail link

Poor Prognosis

Reference Number: 50
Marshall, D. D. & Kornberg, L. J. Overexpression of scatter factor and its receptor (c-met) in oral squamous cell carcinoma. Laryngoscope 108, 1413-7 (1998).
PubMed link      E-mail link

Reference Number: 51
Uchida, D. et al. Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int J Cancer 93, 489-96 (2001).
PubMed link      E-mail link

Reference Number: 52
Aebersold, D. M. et al. Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. Int J Cancer 96, 41-54 (2001).
PubMed link      E-mail link

Reference Number: 53
Cortesina, G. et al. Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases. Int J Cancer 89, 286-92. (2000).
PubMed link      E-mail link

Reference Number: 54
Galeazzi, E. et al. Detection of MET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas. Eur Arch Otorhinolaryngol 254 Suppl 1, S138-43 (1997).
PubMed link      E-mail link

Reference Number: 55
Morello, S. et al. MET receptor is overexpressed but not mutated in oral squamous cell carcinomas. J Cell Physiol 189, 285-90 (2001).
PubMed link      E-mail link

Reference Number: 56
Sawatsubashi, M., Sasatomi, E., Mizokami, H., Tokunaga, O. & Shin, T. Expression of c-Met in laryngeal carcinoma. Virchows Arch 432, 331-5 (1998).
PubMed link      E-mail link

Reference Number: 489
Lo Muzio L, Farina A, Coccia E, Capogreco M, Colella G, Leonardi R, Campisi G, Carinci F. Effect of c-Met expression on survival in head and neck squamous cell carcinoma. Tumour Biol. 27, 115-21 (2006)
PubMed link      E-mail link

Reference Number: 537
Endo K, Shirai A, Furukawa M, Yoshizaki T. Prognostic value of cell motility activation factors in patients with tongue squamous cell carcinoma. Hum Pathol. 37, 1111-6 (2006)
PubMed link      E-mail link

Mutation of Met

Reference Number: 57
Di Renzo, M. F. et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19, 1547-55 (2000).
PubMed link      E-mail link

Reference Number: 968
Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 69, 3021-31 (2009)
PubMed link      E-mail link

Reference Number: 1532
Lacroix L, Post SF, Valent A, Melkane AE, Vielh P, Egile C, Castell C, Larois C, Micallef S, Saulnier P, Goulaouic H, Lefebvre AM, Temam S. MET genetic abnormalities unreliable for patient selection for therapeutic intervention in oropharyngeal squamous cell carcinoma. PLoS One. 9, e84319 (2014)
PubMed link      E-mail link

In vitro studies

Reference Number: 58
Dong, G. et al. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 61, 5911-8 (2001).
PubMed link      E-mail link

Reference Number: 59
Zeng, Q. et al. Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B. J Biol Chem 277, 25203-8 (2002).
PubMed link      E-mail link

Reference Number: 281
Lai JP, Chien J, Strome SE, Staub J, Montoya DP, Greene EL, Smith DI, Roberts LR, Shridhar V. HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene 23, 1439-47 (2004)
PubMed link      E-mail link

Reference Number: 444
Klosek SK, Nakashiro K, Hara S, Shintani S, Hasegawa H, Hamakawa H. CD151 forms a functional complex with c-Met in human salivary gland cancer cells. Biochem Biophys Res Commun336, 408-16 (2005)
PubMed link      E-mail link

Reference Number: 445
Worden B, Yang XP, Lee TL, Bagain L, Yeh NT, Cohen JG, Van Waes C, Chen Z. Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma. Cancer Res. 65, 7071-80 (2005)
PubMed link      E-mail link

Reference Number: 446
Sundelin K, Roberg K, Grenman R, Hakansson L. Effects of cytokines on matrix metalloproteinase expression in oral squamous cell carcinoma in vitro. Acta Otolaryngol. 125, 765-73 (2005)
PubMed link      E-mail link

Reference Number: 733
Daly AJ, McIlreavey L, Irwin CR. Regulation of HGF and SDF-1 expression by oral fibroblasts--implications for invasion of oral cancer. Oral Oncol. 44, 646-51 Epub 2007 Nov 9 (2008)
PubMed link      E-mail link

Reference Number: 926
Scianna M, Merks RM, Preziosi L, Medico E. Individual cell-based models of cell scatter of ARO and MLP-29 cells in response to hepatocyte growth factor. J Theor Biol. 260, 151-60 (2009)
PubMed link      E-mail link

Reference Number: 967
Lui VW, Wong EY, Ho K, Ng PK, Lau CP, Tsui SK, Tsang CM, Tsao SW, Cheng SH, Ng MH, Ng YK, Lam EK, Hong B, Lo KW, Mok TS, Chan AT, Mills GB. Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. Oncogene. 30, 1127-34 (2011)
PubMed link      E-mail link

Reference Number: 1037
Susuki D, Kimura S, Naganuma S, Tsuchiyama K, Tanaka T, Kitamura N, Fujieda S, Itoh H. Regulation of microRNA expression by hepatocyte growth factor in human head and neck squamous cell carcinoma. Cancer Sci. 102, 2164-71 (2011)
PubMed link      E-mail link

Reference Number: 1303
Lim YC, Han JH, Kang HJ, Kim YS, Lee BH, Choi EC, Kim CH. Overexpression of c-Met promotes invasion and metastasis of small oral tongue carcinoma. Oral Oncol. 48, 1114-9 (2012)
PubMed link      E-mail link

Reference Number: 1635
Lim YC, Kang HJ, Moon JH. C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell. Oral Oncol. 50, 633-9 (2014)
PubMed link      E-mail link

Animal models

Reference Number: 667
Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, Giaccone G, Albano R, Comoglio PM, van Dongen GA. Quantitative PET imaging of Met-expressing human cancer xenografts with (89)Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging. 2008 May 20. [Epub ahead of print]
PubMed link      E-mail link

Therapeutic Development

Reference Number: 224
Aebersold, D.M. et al. Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx. Oncogene 22:8519-23 (2003).
PubMed link      E-mail link

Reference Number: 655
Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, Morgan S, Ferris RL, Grandis JR, Siegfried JM. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res. 15, 3740-50 (2009)
PubMed link      E-mail link

Reference Number: 667
Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, Giaccone G, Albano R, Comoglio PM, van Dongen GA. Quantitative PET imaging of Met-expressing human cancer xenografts with (89)Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging. 2008 May 20. [Epub ahead of print]
PubMed link      E-mail link

Reference Number: 967
Lui VW, Wong EY, Ho K, Ng PK, Lau CP, Tsui SK, Tsang CM, Tsao SW, Cheng SH, Ng MH, Ng YK, Lam EK, Hong B, Lo KW, Mok TS, Chan AT, Mills GB. Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. Oncogene. 30, 1127-34 (2011)
PubMed link      E-mail link

Reference Number: 968
Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 69, 3021-31 (2009)
PubMed link      E-mail link

Reference Number: 988
Sen B, Peng S, Saigal B, Williams MD, Johnson FM. Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Clin Cancer Res. 17, 514-24 (2011)
PubMed link      E-mail link

Reference Number: 1047
Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res. 17, 4425-38 (2011)
PubMed link      E-mail link

Reference Number: 1101
Koh YW, Choi EC, Kang SU, Hwang HS, Lee MH, Pyun J, Park R, Lee Y, Kim CH. Green tea (-)-epigallocatechin-3-gallate inhibits HGF-induced progression in oral cavity cancer through suppression of HGF/c-Met. J Nutr Biochem. 22, 1074-83 (2011)
PubMed link      E-mail link

Reference Number: 1287
Singleton KR, Kim J, Hinz TK, Marek LA, Casás-Selves M, Hatheway C, Tan AC, DeGregori J, Heasley LE. A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines. Mol Pharmacol. 83, 882-93 (2013)
PubMed link      E-mail link

Reference Number: 1339
Stabile LP, He G, Lui VW, Thomas S, Henry C, Gubish CT, Joyce S, Quesnelle KM, Siegfried JM, Grandis JR. c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met. Clin Cancer Res. 19, 380-92 (2013)
PubMed link      E-mail link

Reference Number: 1489
Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 31, 3639-46 (2013)
PubMed link      E-mail link

Reference Number: 1530
Zhou Y, Zhao C, Gery S, Braunstein GD, Okamoto R, Alvarez R, Miles SA, Doan NB, Said JW, Gu J, Phillip Koeffler H. Off-target effects of c-MET inhibitors on thyroid cancer cells. Mol Cancer Ther. 13, 134-43 (2014)
PubMed link      E-mail link

Reference Number: 1842
Kumar D, Kandl C, Hamilton CD, Shnayder Y, Tsue TT, Kakarala K, Ledgerwood L, Sun XS, Huang HJ, Girod D, Thomas SM. Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab. JAMA Otolaryngol Head Neck Surg. 141, 1133-9 (2015)
PubMed link      E-mail link

Reference Number: 1887
Baschnagel AM, Galoforo S, Thibodeau BJ, Ahmed S, Nirmal S, Akervall J, Wilson GD. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts. Anticancer Res. 35, 5973-82 (2015)
PubMed link      E-mail link

Reviews

Reference Number: 766
De Herdt MJ, Baatenburg de Jong RJ. HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma. Front Biosci. 13, 2516-26 (2008)
PubMed link      E-mail link

Reference Number: 1048
Lau PC, Chan AT. Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway. Anticancer Drugs. 22, 665-73 (2011)
PubMed link      E-mail link

Reference Number: 1781
Nisa L, Aebersold DM, Giger R, Zimmer Y, Medová M. Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer. Pharmacol Ther. 143, 337-49 (2014)
PubMed link      E-mail link